News
12-15-2010, 11:30 PM
Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).
More... (http://www.news-medical.net/news/20101216/Enzon-in-collaboration-with-NCI-initiates-EZN-2968-and-EZN-2208-Phase-I-studies-for-arresting-tumor-growth.aspx)
More... (http://www.news-medical.net/news/20101216/Enzon-in-collaboration-with-NCI-initiates-EZN-2968-and-EZN-2208-Phase-I-studies-for-arresting-tumor-growth.aspx)